CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

NICO Corporation notes the proof-of-concept study was published in Brain-Computer Interfaces in September and used a modified and miniaturized NICO BrainPath, the world’s first navigated trans-sulcal access technology widely used in Minimally Invasive Parafascicular Surgery (MIPS) for access in the removal of brain tumors and evacuation of hemorrhagic stroke.

Obesity remains a pressing global health concern, with the World Obesity Federation projecting potential economic impacts exceeding $4 trillion by 2035. TCI's innovative technology represents a proactive response to this challenge and offers consumers a natural and powerful weight management solution. The company's strides are expected to drive a transformative shift in the health industry's approach to combating obesity.

he study met its primary endpoint of target lesion failure (TLF) with no TLF events reported in the study arm, demonstrating safety compared to DES. The data were presented by Stefan Verheye, M.D., Ph.D., Interventional Cardiologist at ZNA Cardiovascular Center in Antwerp, Belgium and the study co- principal investigator at the Innovation Program session at the Transcatheter Cardiovascular Therapeutics (TCT) conference today in San Francisco.

"During the autumn, we have visited several of our active eye clinics in the US and we are experiencing great enthusiasm after the promising signals of effect. We also see an increase in recruitment rates after we changed the study protocol and removed the placebo group. We remain committed to our plan to have all patients included in the study during the first quarter of next year and to be able to report 4-month follow-up data thereafter", says Dr. Anna Frostegård, Chief Scientific and Medical Officer at Annexin Pharmaceuticals.

Non-melanoma Skin Cancer: Treatment options include surgery, radiation, and cryotherapy. Surgical intervention is currently the most common treatment for invasive tumors, but it can lead to unfavorable cosmetic outcomes for some presentations

PK051 is a combined drug that targets disaggregates of amyloid-β proteins. There is increasing scientific acceptance that overproduction and/or deposition of amyloid-β is the initial event in Alzheimer’s Disease pathology.

"The data from this study show a correlation between the expansion of TIL-specific clones and tumor response, which provides compelling support for the use of pelareorep-based therapies in immunologically "cold" tumors. In particular, these data, along with the impressive clinical results, support the ability of pelareorep-checkpoint inhibitor combination therapies to meaningfully improve treatment responses in diseases like pancreatic cancer that have resisted immune-based therapeutic approaches," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer at Oncolytics Biotech.